Figure 1.
Laboratory testing of DOACs and expected plasma levels (based on published mass spectrometry data or from the Summary of Product Characteristics) after therapeutic doses.
Notes: aEstimated geometric mean (5/95th percentile) after the administration of rivaroxaban 20 mg once daily for stroke prevention.57 bEstimated median (5/95th percentile) after the administration of apixaban 5 mg twice daily for stroke prevention.3 cEstimated geometric mean (standard deviation) after the administration of edoxaban 60 mg once daily for stroke prevention.58 dEstimated geometric mean (25/75th percentile) after the administration of dabigatran 150 mg twice daily for stroke prevention.2
Abbreviations: anti-FXa, anti-factor Xa; aPTT, activated partial thromboplastin time; Cmax, maximum plasma drug concentration; Ctrough, trough plasma drug concentration; DOAC, direct oral anticoagulant; dTT, diluted thrombin time; ECT, ecarin clotting time; PT, prothrombin time; TT, thrombin time.